Families contacted as hospice services change

Southern Hospice Group is reporting a £3.7m deficit and has agreed service changes across its three Sussex sites, with changes implemented from Monday. The group, which receives about 14% of its funding from the NHS, will end some routine domiciliary, wellbeing and volunteer-led services and stop routine community respite at Chestnut Tree House while keeping all three sites open and prioritising patients with the most complex palliative needs. Management is contacting affected patients and families to ensure continuity of care, but the restructuring reflects material financial pressure on the charity.

Analysis

The immediate operational response — prioritising highest-complexity patients and shedding routine, volunteer-led activity — creates a durable shift in where low-acuity care is delivered. Expect the marginal demand that used to be absorbed pro bono or by hospice volunteers to flow to paid community providers and NHS-contracted agencies, putting upward pressure on spot rates for domiciliary nurses and short-term agency staffing within 1-6 months.

This reallocation also creates a two-speed market for suppliers: vendors of home-based medical devices and remote-monitoring solutions see volume growth for higher-acuity patients who remain at home, while suppliers tied to group-wellbeing and low-intensity services face demand erosion. Supply-chain timing matters — device suppliers with available inventory and local repair/logistics networks will capture most upside in the next 6-12 months; others will lag due to lead times and procurement cycles.

On the capital side, a charity forced to rebalance services increases the probability of asset monetisation, contract handovers, or commercial partnerships with private operators and integrators. That sets up M&A catalysts and contract tender waves over the next 3-12 months — private operators that can scale community nursing quickly or provide tech-enabled care coordination will be in a position to buy assets or win blocks of public contracts.

Reversal risks are concentrated: a rapid, large-scale emergency fundraising campaign or targeted government grant can restore lost services within weeks and compress the commercial opportunity for private players. Monitor local council procurement notices and parliamentary questions for early signals; absent intervention, expect secular re-contracting and modest pricing power for staffing and home-device vendors to persist for 6-18 months.

Key Decisions for Investors

• Long RMD (ResMed) — 12-month horizon. Buy shares or 12-month call spread to capture 20–35% upside if home-monitoring and oxygen concentrator demand rises; stop-loss 10%. Key catalyst: NHS/local procurement wins and increased home-care device utilization within 3–9 months.
• Long PHG (Philips) — 6–12 months. Allocate a tactical position (3–5% portfolio tranche) to play increased demand for home-health and telecare integration; target 15–25% upside, stop-loss 10%. Catalyst: regional supply/servicing contracts and faster device replacement cycles.
• Long HAS.L (Hays plc) — 3–6 months. Buy recruitment-exposure to benefit from higher agency nurse/healthcare staffing demand; target 15–20% upside as spot rates rise, stop-loss 12%. Watch for sequential margin expansion in UK healthcare recruitment metrics.
• Long SRP.L (Serco Group) — 6–12 months. Take a position to capture upside from public contract awards and integration of community services; target 15–30% total return on contract-led replatforming, stop-loss 12%. Catalyst: tender wins and disclosure of new community-care contracts.
• Event monitor / optionality: keep a small discretionary cash sleeve for charity asset sales or distressed transactions over 3–12 months. Be ready to deploy into regional assets or local operators if forced sales surface; size positions to limit single-asset exposure to <2% NAV.